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Quantification of teicoplanin in plasma by LC-MS 
with online sample clean-up and comparison with 
QMS® assay
Abstract
Background: Teicoplanin is a glycopeptide antibiotic used 
for the treatment of infections caused by Gram-positive 
bacteria. There is a good correlation between trough levels 
and clinical outcome, therefore therapeutic drug monitor-
ing is recommended. Here we present a liquid chroma-
tography-mass spectrometry (LC-MS) method with online 
extraction based on turbulent flow chromatography for 
the quantification of the five main components of teico-
planin, A2–1, A2–2, A2–3, A2–4, and A2–5.
Methods: After online extraction, analytical chromatogra-
phy was performed on a Hypersil Gold C8 column under 
acidic conditions. As mass spectrometer, a Q Exactive 
hybrid instrument was used. Samples were prepared by 
adding internal standard and subsequent centrifuga-
tion. Patient samples (n = 125) that had previously been 
analyzed using a commercially available immunoassay 
(QMS® teicoplanin) were re-analyzed by LC-MS.
Results: The imprecision was  < 6.9%, inaccuracy between 
99.6% and 109%, for both, within- and between-day analy-
sis. The method was shown to be free of matrix effects in the 
relevant time ranges and was compared to a commercially 
available immunoassay, QMS® teicoplanin from Thermo 
Fisher Scientific. The LC-MS assay produced comparable 
results to the QMS® assay, the correlation coefficient was 
0.856 (95% confidence interval 0.800–0.896). LC-MS yielded 
lower concentrations than the immunoassay as could be 
demonstrated by the bias of −1.16 mg/L (95% confidence 
interval −1.90–0.43 mg/L) in the Bland-Altman analysis.
Conclusions: This specific, automated, LC-MS assay for 
teicoplanin is suitable for therapeutic drug monitoring.
Keywords: liquid chromatography-mass spectrometry 
(LC-MS); online extraction; teicoplanin; therapeutic drug 
monitoring; turbulent flow chromatography.
*Corresponding author: Dr sc. Daniel M. Mueller, Institute for 
Clinical Chemistry, University Hospital Zurich, Raemistrasse 100, 
8091 Zurich, Switzerland, Phone: +41 44 2552290,  
Fax: +41 44 2554590, E-mail: daniel.mueller@usz.ch
Arnold von Eckardstein and Lanja Saleh: Institute for Clinical 
Chemistry, University Hospital Zurich, Zurich, Switzerland
Introduction
Teicoplanin, discovered back in the 1970s of the last 
century, is an antibiotic drug belonging to the class of 
glycopeptides [1]. It was isolated from fermentation broth 
of an actinomyces species, Actinoplanes teichomyceticus, 
and is not a pure compound but a mixture of five main 
components, teicoplanins A2–1, A2–2, A2–3, A2–4, and 
A2–5 (cf. structure in Figure 1), and one more polar compo-
nent, teicoplanin A3, which is the degradation product of 
teicoplanin A2 [2, 3]. The difference between the five main 
constituents, A2–1 to A2–5, which account for 90%–95% of 
the total product [2], is the length, saturation and branch-
ing of the fatty acid part of the structure of teicoplanin [3].
Teicoplanin inhibits peptidoglycan synthesis and 
therefore interacts with bacterial cell wall synthesis of 
Gram-positive bacteria [2]. During peptidoglycan synthe-
sis a part of the structure binds to the terminal D-Ala-D-Ala 
groups of the muramylpentapeptide, inhibiting further 
synthesis of the bacterial cell wall [4].
Currently, teicoplanin is registered in most European 
countries for the intravenous treatment of infections of 
the heart, bones and joints, skin and soft tissues, airways, 
and also sepsis. Teicoplanin is also orally applied for 
the treatment of pseudomembraneous colitis caused by 
Clostridium difficile [5, 6].
The correlation between trough levels of teicoplanin 
and the clinical outcome is supported by several studies 
[7, 8]. Several authors have highlighted the importance of 
therapeutic drug monitoring to ensure therapeutic con-
centrations of teicoplanin [9–11]. Typically, trough plasma 
levels  < 10 mg/L are regarded as sub-therapeutic; 10–20 
mg/L are targeted for ordinary Gram-positive infections; 
20–60 mg/L are targeted for severe staphylococcal infec-
tions, and  ≥  60 mg/L are regarded as toxic [12].
Several analytical methods are available for thera-
peutic drug monitoring (TDM) of teicoplanin in serum or 
plasma: fluorescence polarization immunoassays (FPIA) 
[13], homogeneous turbidimetric immunoassays [14], 
high-performance liquid chromatography (HPLC) [15–18], 
and liquid chromatography coupled to mass spectrometry 
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(LC-MS) [19, 20], all of them having their advantages and 
disadvantages. Compared with immunological methods, 
chromatographic methods usually are less susceptible 
to interferences. An overview of the chromatographic 
methods for the determination of teicoplanin since 1995 
can be seen in Table 1. Among the chromatographic 
techniques, LC-MS is currently regarded as gold standard 
because of its superior specificity compared with HPLC 
with conventional detection. The main disadvantage of 
LC-MS and chromatographic methods in general, however, 
is the high manual work load compared to immunoassays, 
especially for sample preparation. Therefore, we aimed to 
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Figure 1 Structure of teicoplanin.
(A) Core structure; (B) teicoplanin A2–1; (C) teicoplanin A2–2; (D) teicoplanin A2–3; (E) teicoplanin A2–4; (F) teicoplanin A2–5. R, rest group, 
displayed under (B–F), T, teicoplanin core structure, displayed under (A).
Table 1 Chromatographic methods published in English for the determination of teicoplanin published since 1995.
Author   Method   Sample 
Preparation
  Mobile phase   Stationary 
phase
  Inaccuracy   Imprecision  Method 
comparison
Reed et al. [18]   HPLC-UV   PPT/LLE   Acetonitrile+25 mM 
potassium phosphate 
buffer pH 6.0
  Biophase ODS, 
5 µm, 250 × 4.6 
mm
  90%    < 7.6%  nd
McCann et al. [16]   HPLC-UV   PPT/LLE   Acetonitrile+30 mM 
ammonium acetate buffer 
pH 4.4
  Sphereclone 
C8, 5 µm, 
150 × 4.6 mm
  99.1–
101.8%
   < 2.76%  FPIA
Hanada et al. [15]   HPLC-UV   PPT/LLE   Acetonitrile+50 mM 
potassium phosphate 
buffer pH 4.0
  L-column ODS, 
5 µm, 250 × 4.6 
mm
  nd    < 12%  FPIA
Mochizuki et al. [17]  HPLC-ECD   Filtration   Acetonitrile+100  mM 
phosphate buffer pH 4.4
  Capcell PAK C8, 
5 µm, 150 × 4.6 
mm
  nd    < 5.9%  nd
Fung et al. [19]   LC-MS/MS  PPT   1% ammonium acetate+ 
0.1% formic acid in water 
or methanol
  Acquity UPLC 
BEH C18, 1.7 
µm, 2.1 × 50 mm
  nd    < 13.4%  FPIA
Tsai et al. [20]   LC-MS/MS  PPT   0.1% formic acid in water 
or acetonitrile
  Kinetex C18, 
2.6 µm, 2.1 × 50 
mm
  88.0–
110.6%
   < 14.7%  nd
LLE, liquid/liquid extraction; nd, not done; PPT, protein precipitation.
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minimize the manual work load needed for sample prep-
aration and developed an LC-MS method for the quan-
tification of teicoplanin in human plasma with online 
extraction based on turbulent flow chromatography. As 
the mass spectrometer, a new hybrid instrument consist-
ing of a quadrupol mass filter and a high-resolution Orbit-
rap, a so called Q Exactive, was used.
Materials and methods
Chemicals and reagents
Teicoplanin and vancomycin were purchased from Sigma-Aldrich 
(Buchs, Switzerland). HPLC grade ammonium acetate was purchased 
from Scharlau (Taegerig, Switzerland), formic acid (purum p.a.) from 
Merck (Darmstadt, Germany), and zinc sulfate monohydrate (purum 
p.a.) from Sigma-Aldrich (Buchs). Commercial calibrators and qual-
ity controls were obtained from Thermo Fisher Scientific/Microgenics 
(Passau, Germany).
All solvents were of LC-MS grade. Methanol and 2-propanol 
were purchased from Seelze GmbH (Seelze, Germany), acetonitrile 
from Romil (Cambridge, UK), and acetone from Merck (Darmstadt). 
Purified water was obtained using a central water purification instal-
lation (Burckhalter AG, Worblaufen, Switzerland).
LC-MS analysis
As the mass spectrometer, a Q Exactive hybrid instrument was used 
(Thermo Fisher Scientific, Reinach, Switzerland), controlled by 
Tune (version 2.2 SP1) and XCalibur software (version 2.2 SP 1.48; all 
Thermo Fisher Scientific).
As the ionization interface, electrospray ionization (ESI) was 
used with the following parameters: sheath gas 60 arbitrary units 
(AU), aux gas 20 AU, sweep gas 5 AU, and spray voltage 4 kV. The 
capillary temperature was maintained at 270°C.
Detection was done in the negative full-scan mode with a reso-
lution of 70,000 full width at half maximum (FWHM; calculated for 
m/z 200). For quantification, extracted ion chromatograms with a 
window of 30 ppm of the doubly charged formic acid adduct of the 
teicoplanins and the doubly charged ion of vancomycin were used. 
The following calculated exact masses were used: m/z 960.76880 for 
teicoplanin A2–1, m/z 961.77594 for teicoplanin A2–2 and A2–3, m/z 
968.78412 for teicoplanin A2–4 and A2–5 and m/z 722.70886 for the 
internal standard vancomycin. The masses of teicoplanin A2–1 to A2–
5 were summed up for calibration and calculation of the results. Data 
analysis was performed by LCQuan (version 2.7.0 SP1.28, Thermo 
Fisher Scientific).
The HPLC system consisted of a transcend TLX-1 HTLC online 
extraction system, equipped with two Accela 600 pumps, an HTC 
PAL autosampler and a valve interface module with built-in switch-
ing valves, all controlled by Aria software (version 1.6.2, all Thermo 
Fisher Scientific).
The following eluents were used: 10 mmol/L ammonium acetate 
in water + 0.1% (v/v) formic acid (eluent A), 10 mmol/L ammonium 
Table 2 LC-gradient used in detail. The gradient shape was linear. 
The following eluents were used: 10 mmol/L ammonium acetate 
in water + 0.1% (v/v) formic acid (eluent A), 10 mmol/L ammonium 
acetate in methanol/acetonitrile 50/50 v/v + 0.1% (v/v) formic acid 
(eluent B), acetone/acetonitrile/2-propanol 1/1/1 v/v/v (eluent C).
Time, 
min
  Flow LP, 
mL/min
  %A   %B   %C   Flow EP, 
mL/min
  %A   %B   %C
0   2   99   1     0.3   99   1  
0.50   0.2   99   1     0.3   99   1  
1.33   2       100   0.3   45   55  
4.67   1   30   70     0.3   45   55  
7.17   2   30   70     0.4       100
8.00   2   30   70     0.3     100  
8.33   2   99   1     0.3   99   1  
10.67   2   99   1     0.3   99   1  
EP, eluting pump, used for the analytical chromatography; LP, 
loading pump, used for the online extraction; %A, %B, %C, 
composition of the eluents.
acetate in methanol/acetonitrile 50/50 v/v + 0.1% (v/v) formic acid 
(eluent B), acetone/acetonitrile/2-propanol 1/1/1 v/v/v (eluent C). For 
turbulent flow chromatography online extraction, a Cyclone column 
(50 × 0.5 mm) was used. Analytical separation was achieved on a 
Hypersil Gold C8 column (100 × 3 mm, 3 µm particle size). Chromatog-
raphy was performed at room temperature (approximately 24°C), and 
the LC flow was diverted into waste between 0 and 1.5 min and 8 and 
10.7 min, using a divert valve. The LC method is summarized in Table 2.
Sample preparation
One hundred µL of a commercial calibrator, a commercial quality 
control or a patient sample were crushed with 100 µL of a precipitat-
ing solution consisting of methanol/acetonitrile/aqueous zinc sulfate 
0.1 mol/L 80/10/10 v/v/v containing the internal standard vancomy-
cin at a concentration of 0.1 g/L. Samples were thoroughly vortexed 
and centrifuged at 11700 × g for 10 min at 4°C. The clear supernatant 
was transferred into autosampler vials, which were stored in the 
cooled sample stack at 10°C until analysis. Thirty microliters were 
injected into the system for LC-MS analysis.
Method validation
The commercially available six calibrators ranging from 0 to 100 mg/L 
were prepared as described above. The standard curves were plotted 
as the summed up peak area ratio of the teicoplanins A2–1 to A2–5 to 
the internal standard versus the concentration using a quadratic fit.
Blank matrix samples from six different sources were analyzed 
to test for the specificity of the method.
All three quality control levels were analyzed five times on the 
same day to calculate within-day inaccuracy and imprecision as well 
as on five different days to calculate between-day inaccuracy and 
imprecision. Imprecision was additionally determined using pooled 
patient samples, which were analyzed five times on the same day to 
calculate within-day imprecision as well as on five different days to 
calculate between-day imprecision.
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To estimate the limit of quantification, a signal-to-noise ratio of 
at least 10 achievable on five different days was taken.
Matrix effects were evaluated using the post-column infusion 
method described by Bonfiglio et al. [21]. An aqueous solution con-
taining teicoplanin and vancomycin, each at a concentration of 20 
mg/L, was infused into the column effluent at a flow rate of 10 µL/
min. Concurrently, six samples prepared as described above – with 
the exception of a precipitation solution without internal standard 
– containing neither teicoplanin nor vancomycin have been injected 
by the autosampler. The selected samples included hemolytic, icteric 
and lipemic samples. Resulting chromatograms were examined for 
regions showing ion suppression or enhancement.
Samples were stored according to the instructions by the com-
mercial, CE-marked kit up to maximum 7 days between 2 and 8°C. 
Therefore, sample stability was not evaluated separately. Post-prepa-
ration stability was tested by re-injecting previously prepared stand-
ards stored in the cooled autosampler stack (10°C) and comparing 
the calculated area ratios to the ones of freshly prepared standards.
Method comparison with QMS® teicoplanin 
assay
Teicoplanin was measured with a commercially available homoge-
neous particle-enhanced turbidimetric immunoassay (QMS® teico-
planin, Thermo Fisher Scientific/Microgenics, Passau, Germany), 
performed on a Roche cobas® 8000 clinical-chemistry autoanalyzer 
(Roche Diagnostics, Rotkreuz, Switzerland). The method was used as 
the reference method for the newly developed LC-MS method.
In total 125 patient samples sent to the laboratory for the quan-
tification of teicoplanin were archived after routine analysis by 
immunoassay according to the kit manufacturer’s instructions for a 
maximum of 7 days at 2–8°C before anonymization and re-analysis 
with LC-MS. A total of seven proficiency testing samples from Instand 
(Düsseldorf, Germany) and UK NEQAS (Sheffield, UK), already ana-
lyzed with the immunological method, were also re-analyzed using 
the new method.
Results
LC-MS analysis
A representative chromatogram of teicoplanin is shown in 
Figure 2. For illustrative purposes, teicoplanin A2–1, A2–2 
and A2–3, A2–4 and A2–5, and vancomycin are depicted on 
separate mass traces. Distinction between A2–1, A2–2 and 
A2–3, A2–4 and A2–5, was possible because of their dif-
ferent mass-to-charge ratio. As described in the Methods 
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m/z 960.76880
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Teicoplanin A2-4 and A2-5
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PA: 477,602 counts (A2-4+A2-5)
Internal standard: vancomycin
m/z 722.70886
RT: 2.5 min
PA: 8,078,800 counts
Figure 2 Representative chromatogram of teicoplanin A2–1 to A2–5.
For illustrative purposes, teicoplanin A2–1, A2–2 and A2–3, A2–4 and A2–5, and vancomycin are depicted on separate mass traces. m/z, 
mass-to-charge ratio, PA, peak area count; RT, retention time.
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section, teicoplanin A2–1 to A2–5 were summed up for 
calibration. Retention times were between 6.0 and 6.8 min 
for the teicoplanins and 2.5 min for vancomycin.
Method validation
Calibration was reproducible with correlation coefficients 
for the quadratic fits consistently  > 0.995 in the between-
day analysis. Carryover was always  < 1% in the blank 
sample analyzed immediately after the highest calibrator 
(100 mg/L) in the between-day analysis.
In the six blank matrix samples, no background 
signal was observed, demonstrating good specificity of 
high-resolution mass spectrometry.
The results for inaccuracy and imprecision deter-
mined with both, the commercially available internal 
quality control material and pooled patient samples, are 
summarized in Table 3. Using the commercially available 
internal quality control material, maximal imprecision 
amounted to 3.66% and inaccuracy ranged between 104% 
and 109% for the within day-analyses; for between-day 
analyses, the numbers for imprecision and inaccuracy 
read  < 2.40% and 99.6–105%, respectively. Using pooled 
patient samples, the imprecision was  < 3.87% for within-
day and  < 6.88% for between-day analysis.
Defined by a signal-to-noise ratio of 10, the limit of 
quantification was estimated to be 1 mg/L.
In none of the six analyzed samples for the evaluation 
of matrix effects, ion suppression or enhancement was 
detected in the relevant time ranges where either one of 
the teicoplanins or vancomycin eluted.
Table 3 Inaccuracy and imprecision data of the method for within- 
and between-day analysis.
  Concentration, 
mg/L
  Inaccuracy, 
%
  Imprecision, 
%
Within-day   10.4   106 (n = 6)   3.66 (n = 6)
(commercial QC)   35.8   109 (n = 6)   2.58 (n = 6)
  76.6   104 (n = 6)   1.68 (n = 6)
Within-day   7.52   –   3.87 (n = 5)
(pooled patient 
samples)
  22.0   –   3.68 (n = 5)
Between-day   10.4   101 (n = 5)   2.40 (n = 5)
(commercial QC)   35.8   105 (n = 5)   1.75 (n = 5)
  76.6   99.6 (n = 5)   2.01 (n = 5)
Between-day   7.52   –   6.88 (n = 5)
(pooled patient 
samples)
  22.0   –   5.67 (n = 5)
The table is split into values determined using the commercially 
available internal quality control (QC) material and values 
determined using pooled patient samples.
Post-preparation stability experiments showed that 
prepared standards stored in the cooled autosampler 
stack were stable for at least 3 days, deviating  < 15% com-
pared with freshly prepared standards.
Method comparison with QMS® Teicoplanin 
assay
A linear regression analysis as well as a Passing-Bablok 
fit of the immunological QMS® and the newly developed 
LC-MS methods can be seen in Figure 3. The coefficient 
of correlation was 0.856 (95% confidence interval: 0.800–
0.896). Teicoplanin concentrations measured with LC-MS 
were a bit lower than those obtained with the immuno-
logical method. Upon Bland-Altman analysis the bias 
amounted to −1.16 mg/L (95% confidence interval: −1.90–
0.43 mg/L) (Figure 4).
The proficiency testing samples which were re-ana-
lyzed with the new LC-MS method were within the accept-
ance range of the testing schemes. The mean bias of the 
LC-MS method compared to the mean of the immunologi-
cal methods was −8.29%.
Discussion
In the clinical routine laboratory practice, teicoplanin is 
usually measured by immunoassays [10]. The general dis-
advantage of immunoassays used for TDM is their suscepti-
bility to interferences and cross-reactions. In addition and 
40
45
50
30
35
15
20
25
LC
-M
S,
 m
g/
L
5
10
Passing Bablok fit
1.15x-2.50
Linear fit
1.02x-1.48
0
0 5 10 15 20 25 30 35 40 45 50
QMS® teicoplanin, mg/L
Figure 3 Passing-Bablok (solid line) and linear fit (dotted line) for 
the patient sample comparison (n = 125) between the immunologi-
cal method, QMS® teicoplanin, and the newly developed LC-MS 
method.
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more specifically, teicoplanin immunoassays have been 
reported to suffer from high imprecision especially at low 
concentrations around 10 mg/L which is the clinical deci-
sion cut-off [22]. To overcome these problems, alternative 
methods may be used, e.g., chromatography techniques. 
Previously, teicoplanin was measured by HPLC, usually UV 
detection [16, 23–25]. However, LC-MS is increasingly avail-
able for TDM in clinical laboratories, as it offers superior 
specificity and sensitivity [26]. In this paper, we describe 
the successful development and validation of an LC-MS 
based method that allows the quantification of teicoplanin 
in patient samples under clinical routine conditions.
In clinical routine immunoassays are usually used for 
the TDM of teicoplanin, which was also the case in our 
laboratory before, therefore we have chosen to compare 
our newly developed LC-MS method to an immunoassay. 
The comparability between this immunoassay, the QMS® 
teicoplanin, and our newly developed LC-MS method is 
moderate. However, the correlation coefficient r = 0.856 
(r2 = 0.73) observed by us resembles the previously reported 
correlation between teicoplanin measurements by 
another LC-MS method and FPIA (r2 = 0.86) [19]. Possible 
reasons for the relatively poor correlations include differ-
ent cross-reactivities of the antibodies with the different 
teicoplanins as well as interferences with the immunoas-
say. Another influencing factor is the high imprecision of 
the used immunoassay, especially in the lower therapeu-
tic concentration range ( < 20 mg/L), where we analyzed 
most of the patient samples in this method comparison.
Differences in results measured with different methods 
are a well-known phenomenon in clinical chemistry, 
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Figure 4 Bland-Altman plot for the patient sample comparison 
(n = 125) between the immunological method, QMS® teicoplanin, and 
the newly developed LC-MS method.
Depicted is also the theoretical line of identity (solid line), the 
calculated bias (dotted line) as well as the 95% limits of agreement 
(dashed line).
either for endogenous (e.g., cortisol [27], or Vitamin D 
[28]), or exogenous compounds (e.g., cyclosporine [29]). 
Therefore, care has to be taken to clearly separate both 
methods on the clinical reports in order to enable correct 
trend analyses, which was done for our newly developed 
LC-MS method.
However, a more independent comparison of system-
atic differences between methods is only possible by exter-
nal quality control schemes. The mean bias of our LC-MS 
method versus immunological methods was only −8.29%.
In our study like in a previous one [25] the correlations 
between immunological and chromatographic measure-
ments are closer when the sum of all teicoplanins rather 
than the main component, teicoplanin A2–2 is taken as 
the comparator (data not shown). Summing up of the 
peak areas of all teicoplanins is possible because the sub-
composition of teicoplanin is regulated by governmental 
bodies and therefore always similar [30]. The teicoplanin 
preparation used for the commercial calibrators complies 
with this regulation. The most likely reason for the better 
correlation between immunological and chromatographic 
measurements when using the sum of all teicoplanins 
rather than only the main component is the cross-reac-
tivity of the antibodies used in immunological methods, 
which makes the assay not specific for a distinct teicopla-
nin. In agreement with other authors [25], we decided to 
integrate the peak areas of all teicoplanins for the meas-
urement of total teicoplanin, A2–1 to A2–5, because the 
thereby obtained stronger correlation with the immu-
nological method facilitates the introduction of the new 
method into clinical practice. However, our method, like 
another previously described chromatographic method 
[23], shows a systematic negative bias compared with the 
immunological method.
Compared to the immunological methods, the main 
advantage of our newly developed LC-MS method is the 
much better precision in the lower, therapeutically impor-
tant range. The imprecision of the QMS® teicoplanin assay, 
implemented on the Roche cobas® 8000, was as high as 
21.1% for the within-day assay and 9.5% for the between-
day assay at a concentration of 8.0 mg/L. With variations 
below 3.7% at a concentration of 10.4 mg/L (cf. Table 3) the 
intra- and inter-assay imprecisions of the LC-MS method 
were much lower.
To the best of our knowledge, there are currently only 
two other published applications of LC-MS to TDM of 
teicoplanin [19, 20]. Our method is the first method using 
online extraction based on turbulent flow chromatog-
raphy. This technique allows advanced automation and 
minimizes error- and imprecision-prone manual handling 
steps. A further advantage of this technique towards the 
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protein precipitation step used by Fung et al. [19] and Tsai 
et al. [20] is the higher purity of the extract which reduces 
the susceptibility of the method to matrix effects. In fact 
we noticed during method development that protein pre-
cipitation alone does not eliminate matrix effects affect-
ing the peaks of interest. By contrast, the application of 
the method with online extraction presented in this paper 
to more than 200 “real world” clinical samples has never 
raised any suspicion of matrix effects. As our method 
acquires data by full scan mode, it will detect such matrix 
effects much better than LC-MS methods using multiple 
reaction mode (MRM) on a triple quadrupole mass spec-
trometer, which nowadays are frequently applied to TDM.
Regarding the huge number of potential endo- and 
exogenous interferences, the analysis of only six matrix 
samples from independent sources cannot be considered as 
proof of specificity, although still recommended by the FDA 
guidance for bioanalytical method validation [31]. However, 
the high resolution of 70,000 (FWHM), the high mass of the 
analytes and the ionization in negative ionization mode 
drastically reduce the risk of interferences. In our experi-
ence, the specificity of a resolution of 70,000 (FWHM) is at 
least comparable with the specificity of, e.g., a triple stage 
quadrupole mass spectrometer operated in the MRM mode.
Compared with the triple stage quadrupole apparatus 
available in our laboratory (TSQ Quantum Access Max, 
Thermo Fisher Scientific), the Q Exactive was much more 
sensitive for the quantification of teicoplanin. Due to the 
fact that acquisition is performed in full-scan compared 
to MRM, a key advantage of the Q Exactive is its increased 
flexibility which is especially useful during method 
development or for troubleshooting of specific samples 
complicated by interferences or matrix effects. The main 
drawback of this technology is its price, which is still sub-
stantially higher than that of a comparable triple stage 
quadrupole instrument. Therefore, it is not yet widely 
used in TDM laboratories. However, in our opinion, due to 
its flexibility and sensitivity, the Q Exactive is a welcome 
addition for work also in a routine clinical TDM laboratory.
Post-preparation stability experiments showed that 
teicoplanin was stable for at least 3  days stored in the 
cooled autosampler stack, a fact which is very beneficial 
for application of the assay in a routine laboratory.
Compared with the method of Fung et al. [19] and Tsai 
et  al. [20], our method shows a better precision ( < 6.9% 
vs.  < 13.4% for Fung et  al. [19] and  < 12.6% for Tsai et  al. 
[20] for between-day analysis). However, the run time of 
our method (using HPLC) is significantly longer compared 
with the method of Fung et al. [19] (using UPLC): 10.7 min 
vs. 2.8 min. The runtime of the method of Tsai et al. [20] is 
with 7.5 min in the same range as that of our method. Both 
our method and the one described by Fung et al. [19] have a 
lower limit of quantification of 1 mg/L. The method of Tsai 
et al. [20] indicates lower limits of quantification (0.14–0.32 
mg/L, depending on the sub-component of teicoplanin). 
However, it is questionable whether this is clinically rel-
evant, as therapeutic ranges are significantly higher.
Using a suitable internal standard for the determina-
tion of teicoplanin is still problematic, as described also 
by Fung et al. [19]. LC-MS allows the use of stable isotope 
labeled compounds as the ideal internal standards. 
However, to the best of our knowledge, as yet there is no 
labeled teicoplanin commercially available. The choice of 
our internal standard, vancomycin is not optimal, as van-
comycin is also therapeutically used. However, because 
vancomycin and teicoplanin belong to the same group 
of antibiotics, it is not reasonable to use them concomi-
tantly. There are some situations where the therapy may 
be changed from vancomycin to teicoplanin. However, 
TDM is only recommended in the steady-state of teicopla-
nin dosage, leaving usually enough time for vancomycin 
to be excreted completely from the body. Nevertheless, the 
peak of the internal standard must always be examined 
very carefully and the peak area count compared to the 
one of the standards and quality control in order to detect 
patient samples containing relevant concentrations of 
vancomycin. If relevant concentrations of vancomycin 
are detected, results must be calculated without the use 
of the internal standard, which is also indicated on the 
laboratory report. Another analytical problem is the dif-
ference in retention time between vancomycin and the 
teicoplanins. However, as could be demonstrated by the 
matrix effects experiments, there is for both time ranges 
no relevant matrix effect, which would be the major cause 
for differences in measurement variations between vanco-
mycin and the teicoplanins. We also tested other potential 
internal standards for the determination of teicoplanin. 
Due to their structural difference some led to excessive 
imprecision. Additional differences in polarity led to even 
larger deviations in the retention time between the inter-
nal standard and the teicoplanins as compared to van-
comycin. To conclude, we developed an automated and 
specific LC-MS method using online extraction for the 
TDM of teicoplanin. Compared to a commercially avail-
able immunoassay, QMS® teicoplanin, the LC-MS method 
yields systematically lower levels of teicoplanin. The new 
LC-MS method proved its suitability for TDM of teicopla-
nin both upon clinical application and proficiency testing. 
In our clinical laboratory, we switched TDM of teicoplanin 
to the newly described LC-MS method because of its supe-
rior performance regarding imprecision, especially in the 
lower, therapeutically relevant range.
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